Screening for factor V. Leiden mutation in users ofcombined
oral contraceptives or hormone replacement therapy
CIBULA D.1, UNZEITIG V.2, ŽIVNÝ J.1
Gynekologicko-porodnická klinika 1. LF UK a VFN, Iřaha, přednosta prof. MUDr. J. Živný, DrSc. Gynekologicko-porodnická klinika LF MU a FN, Brno přednosta prof. MUDr. P Ventruba, DrSc |
|
Summary:
Objective: Andysis of the issue of screening for Factor V Leiden mutation (FVL) in users of
combined ord contraceptives (COC) or hormone replacement therapy (HRT).
Design: Review article.
Methods: Review of published facts, andysis of possibilities to screen dl users or to test risk
groups in the current situation in the Czech Republic
Conclusion: 1. Screening for FVL in dl COC or HRT users is not recommended mostly for economicd ressons. 2. Testing for FVL is indicated in women with apositive fanily history of thromboembolic disease and in obese women, if they consider COC or HRT despite our recommendation or in čase there is a medicd indication. 3. Deep venous thrombosis or pulmonary embolism are absolute contrándications of COC or HRT regardless of the presence ofFVL.
Key words:
combined ord contraceptives, hormone replacement therapy, thromboembolic disease, Factor V Leiden mutation, hereditary thrombophilias
|
